醫藥股普遍跑贏大市 騰盛博藥急彈23% 惟歌禮及三葉草吐近6%
恆指兩連吐後,今早在科指及金融分類指數帶動,曾高見19,255,現報19,201,回升106點或近0.6%,總成交額295億元。
醫藥板塊今天普遍跑贏大市,尤其是騰盛博藥-B(02137.HK)結束兩連跌,股價重越20天及10天線,最高見9.48元,現報9.4元,急彈23%,為最強「B仔」,成交急增至2,063萬股,已超越過去三天總成交量。
諾誠健華-B(09969.HK)、藥明巨諾-B(02126.HK)、樂普生物-B(02157.HK)及開拓藥業(09939.HK)反覆升逾2%-35。然而,百心安-B(02185.HK)反覆屢尋底,今早股價高開報6.74元欠承接,掉頭低見5.93元屢創上市新低,現報5.98元,倒跌8%。
百濟神州(06160.HK)續升6.5%報126.8元,股價重越10天線(123.2元)。康希諾生物(06185.HK)反覆回升2.8%報73.1元。藍籌翰森製藥(03692.HK)、中生製藥(01177.HK)和藥明生物(02269.HK)齊升約3%,後者曾高見52.2元。
在線醫療股以藍籌阿里健康(00241.HK)表現較好,股價終止兩連跌,再度挑戰20天線(7.6元),最高見7.62元,現報7.37元,回升2.4%。
然而,新冠及猴痘病毒抑制劑獲美國專利授權歌禮-B(01672.HK)繼昨天以大成交股價飆升53%至八個月高位後,今早曾回吐15%低見4.51元獲承接,現報5元,回吐5.8%。獲高盛升價至3.37元的三葉草生物-B(02197.HK)繼昨天反彈18%後,今早低開後反覆回吐,高低見3.29元/2.98元(守穩百天線2.95元),現報2.99元,回吐5.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.